BCL2 and cancer: The final compound, obatoclax (EC50 0.36 ± 0.1 μM, CC50 1.5 ± 0.33 μM, SI = 4.2) inhibits the Bcl-2 family of proteins and has been investigated as an experimental anti-cancer drug.